Inhibition of Type-5 Phosphodiesterase: Promising Therapy for Pulmonary Hypertension
نویسندگان
چکیده
منابع مشابه
PULMONARY HYPERTENSION Phosphodiesterase type 5 and high altitude pulmonary hypertension
Background: This study explored phosphodiesterase type 5 (PDE5) inhibition as a strategy for treating high altitude pulmonary arterial hypertension (HAPH). Methods: 689 subjects (313 men) of mean (SD) age 44 (0.6) years living above 2500 m were screened for HAPH by medical examination and electrocardiography, and 188 (27%) met the criteria for right ventricular hypertrophy. 44 underwent cardiac...
متن کاملIs inhibition of phosphodiesterase type 5 by sildenafil a promising therapy for volume-overload heart failure?
Phosphodiesterase type 5 (PDE5) is an enzyme that belongs to a large family of cyclic nucleotide PDEs that catalyze cAMP and cGMP. cAMP and cGMP are 2 essential intracellular second messengers regulating many different cellular functions of living cells. PDE5 specifically breaks down the substrate cGMP. Inhibition of PDE5 increases intracellular cGMP levels by inhibiting its degradation. Silden...
متن کاملPhosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension
n engl j med 361;19 nejm.org november 5, 2009 1864 This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are prese...
متن کاملEffect of regular phosphodiesterase type 5 inhibition in hypertension.
There are no published controlled clinical trials of regular phosphodiesterase type 5 inhibitor therapy as a long-term treatment of hypertension. In a randomized, double-blind, 2-way crossover study, 25 otherwise untreated hypertensive subjects were administered 50 mg of sildenafil or matched placebo 3 times daily for 16 days, and the effects on ambulatory blood pressure (BP), clinic BP, arteri...
متن کاملDual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study
BACKGROUND Recent vasodilating drugs have improved prognosis of Pulmonary arterial hypertension (PAH). Some reports describe the merits of combination therapies for PAH, and this study evaluated the efficacy and safety of phosphodiesterase type 5 inhibitors (PDE5i) combination therapy, using sildenafil and tadalafil, for multi-drug-resistant PAH. METHODS We retrospectively analyzed 7 consecut...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Internal Medicine
سال: 2004
ISSN: 0918-2918,1349-7235
DOI: 10.2169/internalmedicine.43.891